Helping high-throughput laboratories increase multiplexing capacity and maximize sequencing throughput without changing established workflows
Read articleHelping high-throughput laboratories increase multiplexing capacity and maximize sequencing throughput without changing established workflows
ReadEnables ultra-low variant detection across a range of key MRD targets in AML, including very large FLT3-ITDs.
ReadOGT’s CytoCell KMT2A Breakapart FISH Probe Kit PDx detects clinically relevant rearrangements that occur in patients with acute leukemia, providing a robust, accessible, rapid turnaround test for KMT2Ar detection.
ReadThrough this partnership, SureSeq™ NGS panel users can gain access to streamlined, high-confidence genomic insights and efficient, scalable reporting from sample to result.
ReadOGT will be moving from plastic packaging to new, sustainable packaging for CytoCell products, an important step forward in our ongoing environmental efforts.
ReadUltra-low variant detection (including very large FLT3-ITDs) enables a stronger characterization of a sample’s current AML status.
ReadImproving upon existing SureSeq™ technology, this latest SureSeq NGS panel unlocks more efficient and expansive genetic profiling for CLL samples
ReadEnables users to replace multiple techniques with a single streamlined NGS process for faster results.
ReadInvestment in new premises to create increase in cutting-edge genomic solutions and collaborative partnerships.
ReadNew NGS assay delivers exceptional coverage, providing a rapid and highly sensitive means of investigating MRD in AML samples
ReadEnhanced NGS portfolio includes Interpret Software updates and enables rapid and confident variant detection even in difficult-to-sequence regions.
ReadExpansion of access to clinical support network and market-leading genomic solutions aims to improve patient outcomes.
Read
Visit International site
Visit Canada site
